C-C Chemokine Receptor 2 and Sarcoidosis: Association with Löfgren's Syndrome

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 10, 2003, Pages 1162-1166

  Spagnolo, Paolo ^b   Renzoni, Elisabetta A ^b   Wells, Athol U ^b   Sato, Hiroe ^b   Grutters, Jan C ^b   Sestini, Piersante ^b   Abdallah, Atiyeh ^b   Gramiccioni, Enzo ^b   Ruven, Henk J T ^b   Du Bois, Roland M ^b   Welsh, Kenneth I ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

Cytokines; Polymorphisms; Sarcoidosis

Indexed keywords

HLA ANTIGEN; NUCLEOTIDE;

ALLELE; ARTICLE; CHEMOKINE RECEPTOR CCR2 GENE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE; GENE LOCATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; LOFGREN SYNDROME; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SARCOIDOSIS; SEX DIFFERENCE;

ARTHRALGIA; ERYTHEMA NODOSUM; FEMALE; GENE FREQUENCY; HAPLOTYPES; HETEROZYGOTE; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; LYMPHATIC DISEASES; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CHEMOKINE; SARCOIDOSIS, PULMONARY; SYNDROME;

EID: 0242472764     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200303-456OC     Document Type: Article

References (34)

1. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, et al. ATS/ERS/ WASOG statement on sarcoidosis: American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:149-173.
2. Grutters JC, Sato H, Pantelidis P, Lagan AL, McGrath DS, Lammers JW, van den Bosch JM, Wells AU, du Bois RM, Welsh KI. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002;165:1119-1124.
3. Hutyrova B, Pantelidis P, Drabek J, Zurkova M, Kolek V, Lenhart K, Welsh KI, Du Bois RM, Petrek M. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;165:148-151.
4. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, Terrin ML, Moller DR, Barnard J, Baughman RP, et al. Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001;164:2085-2091.
5. du Bois RM. Sarcoidosis: do our genes really matter? Am J Respir Crit Care Med 2001;164:725-726.
6. Schurmann M, Reichel P, Muller-Myhsok B, Schlaak M, Muller-Quernheim J, Schwinger E. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med 2001;164:840-846.
7. McGrath DS, Foley PJ, Petrek M, Izakovicova-Holla L, Kolek V, Veeraraghavan S, Lympany PA, Pantelidis P, Vasku A, Wells AU, et al. Ace gene I/D polymorphism and sarcoidosis pulmonary disease severity. Am J Respir Crit Care Med 2001;164:197-201.
8. Katchar K, Wahlstrom J, Eklund A, Grunewald J. Highly activated T-cell receptor AV2S3 (+) CD4 (+) lung T-cell expansions in pulmonary sarcoidosis. Am J Respir Crit Care Med 2001;163:1540-1545.
9. Löfgren S, Lundbäck H. The bilateral hilar lymphoma syndrome: a study of the relation to tuberculosis and sarcoidosis in 212 cases. Acta Med Scand 1952;142:265-273.
10. Scadding JG, Chapell AG, Sutherland I. Familial associations in sarcoidosis. Tubercle 1973;54:87-98.
11. Mc Grath DS, Daniil Z, Foley P, du Bois JL, Lympany PA, Cullinan P, du Bois RM. Epidemiology of familial sarcoidosis in the UK. Thorax 2000;55:751-754.
12. Pasturenzi L, Martinetti M, Cuccia M, Cipriani A, Semenzato G, Luisetti M. HLA class I, II, and III polymorphisms in Italian patients with sarcoidosis: the Pavia-Padova Sarcoidosis Study Group. Chest 1993; 104:1170-1175.
13. Lenhart K, Kolek V, Bartova A. HLA antigens associated with sarcoidosis. Dis Markers 1990;8:23-29.
14. Martinetti M, Luisetti M, Cuccia M. HLA and sarcoidosis: new pathogenetic insights. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:83-95.
15. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis Am J Respir Crit Care Med 1997;156:1601-1605.
16. Sato H, Grutters JC, Pantelidis P, Mizzon AM, Ahmad T, Van Houte AJ, Lammers JW, Van Den Bosch JM, Welsh KI, du Bois RM. HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002;27:406-412.
17. Valente AJ, Rozek MM, Schwartz CJ, Graves DT. Characterization of monocyte chemotactic protein-1 binding to human monocytes. Biochem Biophys Res Commun 1991;176:309-314.
18. Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 1989;169:1449-1459.
19. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994;91:3652-3656.
20. Allavena P, Bianchi G, Zhou D, van Damme J, Jilek P, Sozzani S, Mantovani A. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994;24:3233-3236.
21. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Activation of NK cells by CC chemokines: chemotaxis, Ca2+ mobilization, and enzyme release. J Immunol 1996;156:322-327.
22. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S, Lanzavecchia A. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998;28:2760-2769.
23. Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med 1999;159:2021-2023.
24. Petrek M, Drabek J, Kolek V, Zlamal J, Welsh KI, Bunce M, Weigl E, du Bois R. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2000; 162:1000-1003.
25. Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, Welsh KI. Phototyping: comprehensive DNA typing for HLA-A. B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primers mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995;46:355-367.
26. Ahmad T, Neville M, Marshall SE, Armuzzi A, Mulcahy-Hawes K, Crawshaw J, Sato H, Ling KL, Barnardo M, Goldthorpe S, et al. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet 2003;12:647-656.
27. Fallin D, Schork NJ. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet 2000;67:947-959.
28. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, Charo IF. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997;100:2552-2561.
29. Peters W, Scott HM, Chambers HF, Flynn JL, Charo IF, Ernst JD. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2001;98:7958-7963.
30. Sato N, Kuziel WA, Melby PC, Reddick RL, Kostecki V, Zhao W, Maeda N, Ahuja SK, Ahuja SS. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice. J Immunol 1999;163:5519-5525.
31. Traynor TR, Kuziel WA, Toews GB, Huffnagle GB. CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection. J Immunol 2000;164:2021-2027.
32. Kostrikis L, Huang Y, Moore JP, Wolinski S, Zhang L, Guo Y, Deutsch L, Phair J, Neumann AU, Ho DD. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998;4:350-353.
33. Meyer L, Magierowska M, Hubert JB, Mayaux MJ, Misrahi M, Le Chenadec J, Debre P, Rouzioux C, Delfraissy JF, Theodorou I. CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1: the SEROCO-HEMOCO-SEROGEST Study Groups. J Infect Dis 1999;180:920-924.
34. Ashton LJ, Stewart GJ, Biti R, Law M, Cooper DA, Kaldor JM. Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens. HIV Med 2002;3:91-96.